Giants of Cancer Care® Program Inductees

Genitourinary Cancer

Toni K. Choueiri, MD

Dana-Farber Cancer Institute/Brigham and Womens Hospital/Harvard Medical School

Choueiri is director of the Lank Center for Genitourinary Oncology and of the Kidney Cancer Center at Dana-Farber Cancer Institute/Brigham and Women’s Hospital. He is also the Jerome and Nancy Kohlberg Chair and professor of medicine at Harvard Medical School.
His research has led to the establishment of several novel drugs and combinations including cabozantinib (Cometyx), avelumab (Bavencio), pazopanib (Votrient), and axitinib (Inlyta)-avelumab in advanced renal cell carcinoma (RCC).
Choueiri led the CheckMate 9ER trial (NCT03141177), the results of which. led to the FDA approval of cabozantinib/nivolumab (Opdivo), a combination superior to sunitinib (Sutent) for patients with advanced RCC.
Along with Daniel Heng, MD, Choueiri established the International Metastatic RCC Database Consortium.
Choueiri helped develop one of the first liquid biopsy methods that could detect early stages of kidney cancers with high accuracy. The test was nearly 100% accurate.
His research into biomarkers has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy.
He was coleader for a multinational study to identify COVID-19 risk factors unique to patients with cancer. The results of the CCC19 study (NCT04354701) showed that patients with cancer and COVID-19 had increased risk for 30-day all-cause mortality.

Home

)

SUPPORTED BY